Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

hla-a2-restricted bladder cancer neoantigen peptide sequence and its application

A HLA-A2, 1.HLA-A2 technology, applied in the HLA-A2-restricted bladder cancer tumor neoantigen peptide sequence, the application field of preparing bladder cancer diagnostic reagents and bladder cancer treatment drugs, can solve the problem of high degree of personalization , low mutation rate of tumor neoantigen peptides, high treatment costs and other issues, to achieve the effect of improving treatment effects, reducing treatment costs and increasing coverage

Active Publication Date: 2020-10-30
XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At the same time, due to the low mutation rate of tumor neoantigen peptides in tumor patients and obvious individualized characteristics, the tumor immunotherapy based on tumor antigen peptides is highly individualized and the treatment cost is high. Peptides may not be able to cover a large number of people, so it is necessary to establish a tumor antigen peptide library to achieve a high level of coverage in patients, and to screen new tumor antigens for tumor vaccines or for the establishment of antigen-specific T cells for cell therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • hla-a2-restricted bladder cancer neoantigen peptide sequence and its application
  • hla-a2-restricted bladder cancer neoantigen peptide sequence and its application
  • hla-a2-restricted bladder cancer neoantigen peptide sequence and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0050] The present invention will be described more specifically by way of examples below. It should be understood that the embodiments described here are used to explain the present invention, not to limit the present invention.

[0051] 1. Experimental materials:

[0052] 1. T2 cell line

[0053] T2 cells are B lymphoblastoid immortal cell lines transfected with human leukocyte antigen chimeric molecules. They cannot synthesize β2 microglobulin by themselves, and the expression of human leukocyte antigen on the cell surface is unstable. When exogenous β2 microglobulin is added Exogenous antigenic peptides can be presented to the cell surface to form a stable human leukocyte antigen-antigen peptide complex. Introduced by Stanford University in the United States.

[0054] 2. Reagents

[0055] Antigenic peptide: Shanghai Sangong

[0056] Ficoll separation liquid: Alere Technologies AS 1114547

[0057] 1640 Medium: Gibco

[0058] Fetal bovine serum: Gibco

[0059] β2 mic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an HLA-A2 restrictive bladder cancer tumor new antigen peptide sequence. The sequence is selected from any one or a combination of more of antigen sequences of the following 12genes: CDKN1A gene, RHOB gene, CDC42 gene, DDB1 gene, AHNAK gene, ANP32A gene, ALDH16A1 gene, MET gene, PRDX6 gene, MKI67 gene, GAK gene and DSG3 gene, and the antigen sequences are respectively shown as SEQ ID NO: 1-12. In addition, the invention discloses application of the antigen sequences in preparation of a bladder cancer diagnostic reagent and a bladder cancer therapeutic drug.

Description

technical field [0001] The invention belongs to the field of tumor immunotherapy, and in particular relates to the HLA-A2-restricted bladder cancer tumor neoantigen peptide sequence; in addition, the present invention also relates to the use of the HLA-A2-restricted bladder cancer tumor neoantigen peptide sequence in the preparation of bladder cancer diagnostic reagents and bladder cancer treatment application in medicine. Background technique [0002] Tumor neoantigen (neoantigen) refers to the epitope produced by somatic gene mutation in the process of tumorigenesis and development. Thanks to the implementation of the Tumor Genome Project and the TCGA (The Cancer Genome Atlas, Cancer and Tumor Gene Atlas) public database, the mutation gene information in tumor cells can be obtained through bioinformatics analysis, thus forming a tumor genome sequence-based database. The concept of tumor neoantigen profiles. On the one hand, it reflects the mutation status of tumor cells ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/47A61K39/00A61P35/00A61P13/10G01N33/68G01N33/574
CPCA61K39/00A61P13/10A61P35/00C07K14/4748G01N33/57407G01N33/68
Inventor 沈海波王颖王晨段黄琪曹志伟
Owner XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com